Elena Garralda

机构：Hebron University, Universitat Autònoma de Barcelona, Instituto Oncológico Dr. Rosell, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology · ORCID：0000-0002-4412-7842

发表论文 739 篇 · 总被引 10904 次 · h-index 48

代表论文

• Abstract CT063: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1/2 study (2026 · Cancer Research · 被引 1)
• Data from Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors (2026)
• Supplementary Data 1 from Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors (2026)
• Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors (2026 · Journal for ImmunoTherapy of Cancer)
• Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion (2026 · Cancer)
• Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR -Altered Solid Tumors (2026 · Clinical Cancer Research)